Olverembatinib
Small moleculeexperimental
Clinical trial activity
33 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
22
Phase 3
5
Phase 4
0
Earliest trial started Jul 11, 2018 (NCT03594422)
Timeline
Indications
Studied for
- Drugs, Investigational · Phase 2
- Drug Therapy · Phase 3
- Gastrointestinal Stromal Tumors · Phase 3
- Hematopoietic Stem Cell Mobilization · Phase 2
- Intestinal Neoplasms · Phase 1
- Leukemia · Phase 1
- Leukemia, Lymphoid · Phase 3
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 3
- Leukemia, Myeloid · Phase 1
- Leukemia, Myeloid, Accelerated Phase · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 3
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Mutation · Phase 2
- Myeloproliferative Disorders · Phase 2
- Neoplasms · Phase 1
- Philadelphia Chromosome · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Protein-Tyrosine Kinases · Phase 2
- Tyrosine Kinase Inhibitors · Phase 3
Mechanism of action
- Bcr/Abl fusion proteinINHIBITOR
Bcr/Abl fusion protein inhibitor
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1- Mol. weight
- 532.57 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2316582 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07178912 | Phase 2 | Feb 27, 2026 | Amgen, Ascentage Pharma Group Inc., University of Texas at Houston |
| NCT07282093 | Phase 1 | Dec 31, 2025 | Ascentage Pharma Group Inc. |
| NCT06817720 | Phase 2 | Jul 30, 2025 | Ascentage Pharma Group Inc., University of Texas at Houston |
| NCT07152041 | Phase 3 | Mar 28, 2025 | China Academy of Chinese Medical Sciences, Chinese Academy of Medical Sciences |
| NCT06757855 | Phase 1/Phase 2 (Phase 2) | Jan 15, 2025 | China Academy of Chinese Medical Sciences |
| NCT06754267 | Phase 2 | Dec 31, 2024 | Zhejiang University |
| NCT06658925 | Phase 2 | Nov 1, 2024 | China Academy of Chinese Medical Sciences |
| NCT06640361 | Phase 3 | Oct 31, 2024 | Ascentage Pharma Group Inc., Sun Yat-Sen University |
| NCT06401603 | Phase 1 | Aug 6, 2024 | Ascentage Pharma Group Inc., University of Texas at Houston |
| NCT06481228 | N/A | Jun 4, 2024 | China Academy of Chinese Medical Sciences |
| NCT06423911 | Phase 3 | Feb 5, 2024 | Ascentage Pharma Group Inc. |
| NCT06220487 | Phase 2 | Feb 1, 2024 | Southern Medical University |
| NCT06578546 | Phase 2 | Feb 1, 2024 | Soochow University |
| NCT07074496 | Early Phase 1 (Phase 1) | Jan 1, 2024 | Fundamenta Therapeutics, Ltd., Soochow University |
| NCT06082934 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2023 | Xijing Hospital |
| NCT06051409 | Phase 3 | Sep 2, 2023 | Ascentage Pharma Group Inc., Jiao Tong University, Suzhou Medical College |
| NCT05931757 | Phase 2 | Jul 1, 2023 | Soochow University |
| NCT05603156 | N/A | Oct 30, 2022 | Chinese Academy of Medical Sciences |
| NCT05594784 | Phase 2 | Oct 8, 2022 | Chinese Academy of Medical Sciences |
| NCT05466175 | Phase 2 | Oct 1, 2022 | Soochow University |
Showing 20 of 33 trials
Page 1 / 2
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascentage Pharma Group Inc. | For profit | 15 | 12 | 4 | 2018 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 5 | 5 | 4 | 2022 |
| Soochow University | Academic/Hospital | 5 | 5 | 2 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 4 | 2 | 4 | 2022 |
| Peking University | Academic/Hospital | 4 | 0 | 2 | 2019 |
| Southern Medical University | Academic/Hospital | 3 | 3 | 1 | 2021 |
| Sun Yat-Sen University | Academic/Hospital | 3 | 0 | 3 | 2018 |
| University of Texas at Houston | Academic/Hospital | 3 | 3 | 2 | 2024 |
| Amgen | For profit | 1 | 0 | 1 | 2026 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Fundamenta Therapeutics, Ltd. | For profit | 1 | 0 | 1 | 2024 |
| Guangdong Second Provincial Traditional Chinese Medicine Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Suzhou Medical College | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Tanner Pharma Group | For profit | 1 | 0 | 1 | — |
| Xijing Hospital | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2024 |
18 organizations
Page 1 / 1